NeOnc Technologies Appoints David Choi as Chief Accounting Officer with Significant Equity Grant
NTHI has more than doubled off its 52-week low of $3.2.
Summary
NeOnc Technologies Holdings, Inc. has appointed David Choi as its new Chief Accounting Officer, effective March 12, 2026, bolstering its financial leadership with a seasoned CPA and granting him 170,000 restricted shares.
Key Events · Executive and Board Changes · NTHI
-
New Chief Accounting Officer Appointed
David Choi was appointed as Chief Accounting Officer, effective March 12, 2026, bringing over a decade of experience in financial reporting and internal controls.
-
Significant Equity Compensation
Mr. Choi received a grant of 170,000 restricted shares under the 2023 Equity Incentive Plan, with 53,333 shares vesting immediately and the remainder vesting over time and based on performance.
-
Strengthens Financial Leadership
This appointment is expected to enhance the company's accounting, financial reporting, internal controls, and corporate governance functions during a period of clinical advancement and global expansion.
Analysis · NTHI · Life Sciences
The appointment of David Choi as Chief Accounting Officer is a positive development for NeOnc Technologies, particularly as the company is in a clinical-stage and expanding its operations. Mr. Choi's extensive background in accounting, financial reporting, and internal controls from top advisory firms like Blythe Global Advisors, Grant Thornton, and Ernst & Young is crucial for strengthening the company's financial infrastructure and ensuring compliance as a public entity. The compensation package, including a base salary of $162,500 and a grant of 170,000 restricted shares, aligns with attracting experienced C-suite talent. This move enhances corporate governance and financial oversight, which is vital for investor confidence and future growth.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 29.5% of the 2875 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTHI was trading at $8.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $203.5M. The 52-week trading range was $3.20 to $25.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.